
The Trump Effect on Biopharma: FDA Disruption, Tariffs, and Funding Cuts
AG Capital Advisors CEO Audrey Greenberg discusses FDA disruption, NIH funding volatility, tariffs, AI ambiguity, and how biopharma leaders can navigate the new political reality across CGT, biologics, vaccines, and small molecules. Last month, we asked …